Vectra® is an advanced blood test that measures inflammation caused by your rheumatoid arthritis (RA), predicts your risk of developing permanent joint damage, and helps monitor disease activity and how your treatment plan is working.
Vectra is a blood test based on 12 biomarkers (proteins, hormones and growth factors) that are linked to Rheumatoid Arthritis. Vectra accounts for your age, gender and body fat composition to provide a personalized measure of inflammation caused by your disease.

Multiple Vectra Scores over time provide you with a road map of your disease activity
• Multiple Vectra Scores allows you and your doctor to see how your treatment plan is working and how well your inflammation is being controlled
• A change of 8 or more units in the Vectra Score will indicate a positive or negative change in inflammation

Your Vectra Score falls into one of three categories: low, moderate or high
• Your category reflects your risk of radiographic progression (permanent joint damage)
• The low category being the most desirable category
• The high category being the greatest risk for joint damage and other health risks, such as cardiovascular disease
• The Vectra report will provide the score reflecting your current level of RA inflammation and your percentage risk of radiographic progression (RP) within 1-year

More detailed information about Vectra, your personalized score, can be found on the following pages
Understanding Your Result: The Vectra Score

Your Vectra Molecular Result includes 3 parts

<table>
<thead>
<tr>
<th>Vectra Score</th>
<th>Risk of RP</th>
<th>Change in Score</th>
<th>Vectra Score Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>72</strong></td>
<td><strong>20%</strong></td>
<td><strong>↑</strong></td>
<td><strong>High Vectra Score: 72</strong></td>
</tr>
<tr>
<td>HIGH</td>
<td><strong>1-Year Risk of Radiographic Progression</strong></td>
<td><strong>Meaningful Increase ≥8 Units</strong></td>
<td>Patient has a High Vectra Score that increased by 8 or more units from the previous score, which was also in the High category. Patient is at increased risk for radiographic progression. Consider adjusting treatment regimen to reduce inflammation, and retesting at the next clinical visit.</td>
</tr>
</tbody>
</table>

1. **Vectra Score**: This is your personalized Vectra Score that measures 12 biomarkers (protein, growth factors and hormones) that have been implicated in RA. The score is personalized to you by factoring in your age, gender and body fat (measured by leptin), all of which can affect levels of inflammation.¹

2. **Risk of RP**: This is your risk of rapid radiographic progression (RP) over the next 1 year.

3. **Change in Score**: If this is your first Vectra test, there will be no change in score measure to provide, your report will state “Meaningful Change Not Calculated.” If you have had previous Vectra testing, the Change in Score section will show the difference between your previous and current score and will indicate if there has been a meaningful change, or no change, in disease activity.

4. **Vectra Score Interpretation**: Provides a more detailed explanation of your Vectra Score, your disease activity category, risk of radiographic progression and treatment plan suggestions.

Your personalized Vectra Score is reported as a number on a scale from 1 to 100. Your Vectra Score will be color coded, based on the level of disease activity and inflammation, and will fall into low (1-29), moderate (30-44) or high (45-100).

1. **Vectra Score**: 24
   - **LOW**
   - **(1-29)**
   - A Vectra Score in the low category means that your RA disease activity and inflammation is low. Generally, this means your RA is being well controlled by your current treatment plan.

2. **Vectra Score**: 37
   - **MODERATE**
   - **(30-44)**
   - A Vectra Score in the moderate category means that your RA disease activity and inflammation is higher than the ideal (the low disease activity category), but is not as concerning as a score in the high disease activity category.

3. **Vectra Score**: 72
   - **HIGH**
   - **(45-100)**
   - A Vectra Score in the high category means that your RA disease activity and inflammation is high and could suggest that your RA may not be responding to your current treatment. Vectra Scores in the high disease activity category are known to be associated with a higher risk of permanent joint damage.²
Understanding Your Result:
Radiographic Progression (RP)

19% of patients in clinically-defined remission had progression of radiographic joint damage over 1-year.¹

Visible effects of joint damage and deterioration that may be observed on x-ray

Risk of RP
- 20%
- 1-Year Risk of Radiographic Progression

Inflammation can be more than painful and swollen joints. Inflammation can affect your entire body, including your organs. Vectra is an objective measure of your disease state and inflammation that goes beyond signs and symptoms.⁶,⁷
Understanding Your Result: Change in Score

Changes of 8 or more in high and moderate Vectra Scores represent a meaningful change in RA inflammation. An increase in score by 8 or more units indicates an increasing level of inflammation, an increased risk of joint damage, and may indicate a need to change the patient’s treatment. A decrease in score by 8 or more units indicates a decrease in disease activity and a lower risk of joint damage, indicating that current treatment is working.4,5

The change in Vectra Score reflects the change in inflammation making it a useful tool to help guide medical management decisions when used over time.4

Changes of 8 or more in high and moderate Vectra Scores represent a meaningful change in RA inflammation. An increase in score by 8 or more units indicates an increasing level of inflammation, an increased risk of joint damage, and may indicate a need to change the patient’s treatment. A decrease in score by 8 or more units indicates a decrease in disease activity and a lower risk of joint damage, indicating that current treatment is working.4,5

The Vectra Scores Over Time graph represents how your RA disease and inflammation are trending. Frequent testing provides greater insight to your disease state. Your initial score is considered a baseline score and will be compared to future scores to identify a meaningful change.4

If there is a change in Vectra Score of 8 or more units representing a Meaningful Change it will be indicated in the Vectra Scores Over Time graph.

A meaningful change of ≥8 helps guide treatment decisions.4
Understanding Your Result: Vectra Score Interpretation

Low Score (1-29) Consider...

• No treatment change may be needed. Talk to your doctor about retesting in 6 to 12 months, or sooner if indicated. If your score is considered low or is continuing to decrease over time (2 or more consecutive tests), your doctor may choose to reduce your current treatment.

Moderate Score (30-44) Consider...

• Talk to your doctor about any treatment changes if your Vectra Score has increased by 8 or more units or if there has not been a significant decrease when compared to your previous Vectra Score. A change to your treatment may mean increasing your current medication or considering a new medication. Talk to your doctor about retesting in 3 months.

• With a Vectra Score in the moderate category, it is also possible that no treatment change is needed. For example, if your score has decreased by 8 or more units since your previous Vectra Score, this would demonstrate a significant decrease in your disease activity, and your doctor may recommend that you continue with your current treatment. If you have recently changed your treatment dose or your medication, your doctor may recommend that you continue with your current treatment. Talk to your doctor about retesting in 3 months.

High Score (45-100) Consider...

• Your doctor may consider a change to your treatment if your score has not decreased by 8 units since your previous Vectra test. A change to your treatment may mean increasing your current medication or considering a new medication. Talk to your doctor about retesting in 3 months.

• If your score has decreased by 8 or more units since your previous Vectra Score, or if you have recently changed your treatment dose or your medication, your doctor may recommend that you continue with your current treatment plan. Talk to your doctor about retesting in 3 months.

*The Vectra Score Interpretation provides recommended treatment guidance. Only a medical professional can make treatment decisions concerning the medical management of patients. Recommendations data is currently in study, clinical trial is ongoing.

Understanding Risk for Radiographic Progression (Permanent Joint Damage)

Patients in the high and moderate categories are considered to have uncontrolled inflammation, and may require treatment modification. Vectra is the best predictor of radiographic progression and permanent joint damage. Studies have shown that the risk of radiographic progression is higher in patients with high Vectra Scores, even in cases where the CRP and ESR were low. Patients with a lower Vectra Score had less radiographic progression.2,9

Regular testing is recommended in order to accurately monitor your disease and treatment.
**Individual Biomarker Results**

The Vectra Score is calculated from the analysis of 12 biomarkers (proteins, growth factors, and hormones) that have been linked to RA. Each biomarker represents a different biological pathway (proteins, growth factors, and hormones) that have been linked to RA and carries different weight in the Vectra algorithm.

- **Vectra CRP concentrations** may differ from those provided by other labs and cannot be used interchangeably.
- **Leptin** as a measure of adiposity (body mass) is used in calculation of the Vectra Score.

The Vectra test is intended for clinical use. Crescendo Bioscience Inc. and Myriad Genetics, Inc. developed Vectra and Crescendo Bioscience, Inc. a Myriad Genetics Company.

**Vectra Report Header**

Your information will include your Vectra patient ID number and your test ID number, also known as test requisition number (TR). This test ID will also appear on any billing information as your account number.

**Monitoring your score over time is key to understanding your disease progression or improvement.**

---

**Complete Vectra Score History**

<table>
<thead>
<tr>
<th>COLLECTION DATE</th>
<th>SCORE</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/15/2019</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>10/20/2019</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>01/30/2020</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>04/25/2020</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

*As of December 4, 2017 the Vectra Score is adjusted based on the age, gender, and adiposity of the patient.*
Your score and test results will be sent to your provider’s office. Use this test to discuss treatment plans and treatment goals with your provider.

All current scores and future Vectra Scores can be accessed on the patient portal, myVectra. To sign up for myVectra, go to VectraScore.com and click on myVectra logo at the top, right hand side of page. Vectra Scores will appear in myVectra two weeks after the test has been analyzed and reported.

You may also access your score through the myVectra application (app) by linking your myVectra portal login to the app. Go to you the App Store or Google Play Store to download the app. The myVectra app allows you to track your RA symptoms, creates visual snapshots and log other tests you may take. Capture all your symptoms in the app then download a PDF summary for you to take to your next rheumatologist appointment.

Disease Management is a Shared Effort That Combine:

- **Patient Assessment**
- **Physician Assessment**
- **Molecular Assessment**

**Vectra**

molecular assessment of 12 biomarkers

Generate a personalized report of symptoms and medication in myVectra and take to your next appointment

**Vectra should be used in conjunction with your doctor’s assessment and your self-assessment.** It is important to factor in all three assessments, even when they do not agree. Be honest with your doctor about how you are feeling and if you have any questions about your Vectra Score. Track your symptoms to provide your doctor with a comprehensive summary of your disease symptoms.10
Patient Support & Resources

VectraScore.com
Your online resource to learn more, hear patient stories and link to additional patient information

myVectra Patient Portal
myVectra™ provides you access to your Vectra Scores

1. Go to VectraScore.com
2. Click the myVectra link at the top right corner
3. Click ‘Create an Account’

VectraVoice
Patient blog and newsletter
- Go to VectraScore.com
- General information about living with RA
- On the right sidebar prompt click newsletter icon to Signup for VectraVoice newsletter

If you encounter any financial hardship, we will work directly with you toward your complete satisfaction. If you have any questions regarding the cost of testing, please contact Myriad.

VectraScore.com/affordability/
- billinghelp@myriad.com
- 1-877-743-8639

Go to Google Play store or Apple App Store to download the free myVectra App
- Log symptoms to track disease
- Link to my Vectra portal and access Vectra Scores on mobile device
- Track medications and other tests
- Download and print your activity for our next appointment

Patient Medical Support
A team of highly-trained medical liaisons is available by phone or email to help answer questions regarding Vectra results.

Phone: 877-743-8639 x1984  //  Email: VectraMed@myriad.com

Vectra Customer Service 877-743-8639 and VectraCS@myriad.com
Notice and Statement Concerning Nondiscrimination and Accessibility

Discrimination is Against the Law

Myriad complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Myriad does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Aids and Services

Myriad provides free aids and services to people with disabilities to communicate effectively with us, such as TTY/TTD calls or written information in suitable formats. Myriad will also provide free language services to people whose primary language is not English through qualified interpreters.

If you need these services, contact Ms. Christy Garcia:

Christy Garcia
Compliance Director
320 Wakara Way
Salt Lake City, UT 84108
Telephone: (513) 701-0804
Fax: (513) 440-1781
Email: compliance@myriad.com

Grievances

If you believe that Myriad has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance by mail, telephone, fax, or email. If you need help filing a grievance, Ms. Garcia is available to help you (see contact information above).

Grievance Procedure

1. Any person who believes someone has been subjected to discrimination by Myriad on the basis of race, color, national origin, sex, age or disability may file a grievance with Myriad. It is against the law for Myriad to retaliate against anyone who opposes discrimination, files a grievance, or participates in the investigation of a grievance.

2. Grievances must be submitted within 60 days of the date the person filing the grievance becomes aware of the alleged discriminatory action.

3. The complaint must be in writing, containing the name and address of the person filing it. The complaint must state the problem or action alleged to be discriminatory and briefly describe the remedy or relief sought.

4. Myriad will conduct an investigation of the complaint. This investigation may be informal, but it will be thorough, affording all interested persons an opportunity to submit evidence relevant to the complaint. Myriad will maintain the files and records relating to such grievances pursuant to its document retention policies. To the extent possible, and in accordance with applicable law, Myriad will take appropriate steps to preserve the confidentiality of files and records relating to grievances and will share them only with those who have a need to know.

5. Myriad will issue a written decision on the grievance, based on a preponderance of the evidence, no later than 30 days after its filing, including a notice to the complainer of their right to pursue further administrative or legal remedies.

6. The person filing the grievance may appeal Myriad’s decision in writing to the President of Myriad within 15 days of receiving Myriad’s initial decision. The President will issue a written decision in response to the appeal no later than 30 days after its filing.

7. Individuals seeking access to Section 1557 and its implementing regulations may be facilitated by contacting Ms. Garcia (see contact information above).

8. The availability and use of this grievance procedure does not prevent a person from pursuing other legal or administrative remedies, including filing a complaint of discrimination on the basis of race, color, national origin, sex, age or disability in court or with the U.S. Department of Health and Human Services, Office for Civil Rights. A person can file a complaint of discrimination electronically through the Office for Civil Rights Complaint Portal, which is available at: https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
200 Independence Avenue, SW
Washington, D.C. 20201

9. Complaint forms are available at: http://www.hhs.gov/ocr/office/file/index.html. Such complaints must be filed within 180 days of the date of the alleged discrimination. Myriad will make appropriate arrangements to ensure that individuals with disabilities and individuals with limited English proficiency are provided auxiliary aids and services or language assistance services, respectively, if needed to participate in this grievance process. Ms. Garcia will be responsible for such arrangements.

Español (Spanish)

Myriad cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo. ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-513-701-0804.

简体中文 (Chinese)

Myriad遵守适用的联邦民权法律规范，不因种族、肤色、民族血统、年龄、残疾或性别而歧视任何人。

请注意：如果您使用简体中文，您可以免费获得语言援助服务。请致电1-513-701-0804。

Tiếng Việt (Vietnamese)

Myriad tuân thủ các quy định liên quan đến quyền lợi của người锈和 không phân biệt đối xử trên chủng tộc, màu da, nguồn gốc quốc gia, gia đình, tuổi tác hayolu thực hiện các quyền này. CHÚ Y: Nếu bạn muốn điều chuyển, có thể liên hệ với tôi, bà Garcia, ở số 1-513-701-0804.

한국어 (Korean)

Myriad는 연방 공공기관의 허위를 수반하여 인종, 피부색, 출신 국가, 연령, 장애 또는 성별을 이유로 차별하지 않습니다. 한편, 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-513-701-0804번으로 전화해 주십시오.

Aids and Services

Myriad will provide free language services to people whose primary language is not English through qualified interpreters.

If you need these services, contact Ms. Garcia (see contact information above).
“Because of Vectra, I’ve become an active, informed member of my healthcare team.”

- Stacie Burgess

### MY VECTRA LOG

[VectraScore.com](http://VectraScore.com)

<table>
<thead>
<tr>
<th>Date</th>
<th>Vectra Score</th>
<th>Change From Previous Score</th>
<th>Medication / Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**References:**

Vectra® and CreakyJoints® Are Working Together to Improve the Lives of Rheumatoid Arthritis Patients

CreakyJoints is a 20-year-old non-profit digital community for millions of arthritis patients and caregivers worldwide who seek:

- Education
- Advocacy
- Support
- Patient-centered research

Find out more at
CreakyJoints.org/vectra

VectraScore.com / 1-877-743-8639

Intended use, Vectra is to be used in conjunction with standard clinical practice for the assessment of disease activity in patients with rheumatoid arthritis.

Vectra is validated for use in adults diagnosed with RA. Test results are intended to aid in the assessment of disease activity in RA patients when used in conjunction with standard clinical assessment. This test is not intended or validated to diagnose RA. ©2020 Myriad Genetics, Inc. All rights reserved. Myriad, Vectra, myVectra and the associated logos are trademarks or registered trademarks of Myriad Genetics, Inc. and its affiliates in the United States and other jurisdictions. MGMKT-00439 Rev C / 4-20